Drug-subphenotype interactions for cancer in type 2 diabetes mellitus

Nature Reviews Endocrinology

Volumn 11, Issue 6, 2015, Pages 372-379

  Yang, Xilin ^a   Lee, Heung M ^a   Chan, Juliana C N ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SOMATOMEDIN C; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; CHOLESTEROL; STEROL REGULATORY ELEMENT BINDING PROTEIN;

ALBUMINURIA; BREAST CANCER; CANCER GROWTH; CANCER RISK; CARCINOGENESIS; CELL METABOLISM; CHINESE; CHOLESTEROL BLOOD LEVEL; COLORECTAL CANCER; DYSLIPIDEMIA; ENERGY METABOLISM; HEMATOLOGIC MALIGNANCY; HEPATITIS B; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFECTION; INFLAMMATION; INSULIN RESISTANCE; KIDNEY CARCINOMA; LIPID METABOLISM; LIVER CANCER; LIVER CELL CARCINOMA; LUNG CANCER; METABOLIC SYNDROME X; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; COHORT ANALYSIS; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HONG KONG; METABOLISM; NEOPLASMS; PHENOTYPE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; REGISTER;

AMP-ACTIVATED PROTEIN KINASES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HONG KONG; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN-LIKE GROWTH FACTOR I; NEOPLASMS; PHENOTYPE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGISTRIES; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SIGNAL TRANSDUCTION; STEROL REGULATORY ELEMENT BINDING PROTEINS; TRIGLYCERIDES;

EID: 84929946549     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2015.37     Document Type: Review

References (100)

1. Yang, X. et al. Independent associations between low-density lipoprotein cholesterol and cancer among patients with type 2 diabetes mellitus. CMAJ 179, 427-437 (2008).
2. Jee, S. H. et al. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 293, 194-202 (2005).
3. Stattin, P. et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care 30, 561-567 (2007).
4. Yang, X. et al. Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes 59, 1254-1260 (2010).
5. Saydah, S. H. et al. Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiol. Biomarkers Prev. 12, 412-418 (2003).
6. Johnson, J. A. & Bowker, S. L. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 54, 25-31 (2011).
7. Roumie, C. L. et al. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA 311, 2288-2296 (2014).
8. Currie, C. J., Poole, C. D., Evans, M., Peters, J. R. & Morgan, C. L. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J. Clin. Endocrinol. Metab. 98, 668-677 (2013).
9. Lewis, J. D. et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 34, 916-922 (2011).
10. Yang, X. et al. Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry. Diabetes Res. Clin. Pract 90, 343-351 (2010).
11. Zhang, P., Li, H., Tan, X., Chen, L. & Wang, S. Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol. 37, 207-218 (2013).
12. Gerstein, H. C. et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N. Engl. J. Med. 367, 319-328 (2012).
13. Scirica, B. M. et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 369, 1317-1326 (2013).
14. Home, P. D. et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia 53, 1838-1845 (2010).
15. Levin, D. et al. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia 58, 493-504 (2014).
16. Andersson, T., Alfredsson, L., Kallberg, H., Zdravkovic, S. & Ahlbom, A. Calculating measures of biological interaction. Eur. J. Epidemiol. 20, 575-579 (2005).
17. Yang, X. et al. Validation of methods to control for immortal time bias in a pharmacoepidemiologic analysis of renin-angiotensin system inhibitors in type 2 diabetes. J. Epidemiol. 24, 267-273 (2014).
18. Kong, A. P. et al. Additive effects of blood glucose lowering drugs, statins and renin-angiotensin system blockers on all-site cancer risk in patients with type 2 diabetes. BMC Med. 12, 76 (2014).
19. Yang, X. L. et al. Addressing different biases in analysing drug use on cancer risk in diabetes in non-clinical trial settings-what, why and how? Diabetes Obes. Metab. 14, 579-585 (2012).
20. Rothman, K. J. & Greenland, S. Causation and causal inference in epidemiology. Am. J. Public Health 95 (Suppl. 1), S144-S150 (2005).
21. Yang, X. L. et al. Predicting values of lipids and white blood cell count for all-site cancer in type 2 diabetes. Endocr. Relat. Cancer 15, 597-607 (2008).
22. Yang, X. et al. Low HDL cholesterol, metformin use, and cancer risk in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes Care 34, 375-380 (2011).
23. Yang, X. et al. Low triglyceride and nonuse of statins is associated with cancer in type 2 diabetes mellitus: the Hong Kong Diabetes Registry. Cancer 117, 862-871 (2011).
24. Yang, X. et al. Low LDL cholesterol, albuminuria, and statins for the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes Care 32, 1826-1832 (2009).
25. Yang, X. et al. Synergistic effects of low LDL cholesterol with other factors for the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry. Acta Diabetol. 49 (Suppl. 1), S185-S193 (2012).
26. Alsheikh-Ali, A. A., Trikalinos, T. A., Kent, D. M. & Karas, R. H. Statins, low-density lipoprotein cholesterol, and risk of cancer. J. Am. Coll. Cardiol. 52, 1141-1147 (2008).
27. Zhao, W. et al. HDL Cholesterol and cancer risk among patients with type 2 diabetes. Diabetes Care 37, 3196-3203 (2014).
28. Jafri, H., Alsheikh-Ali, A. A. & Karas, R. H. Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy. J. Am. Coll. Cardiol. 55, 2846-2854 (2010).
29. Kahn, S. E. The relative contributions of insulin resistance and β-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 46, 3-19 (2003).
30. Yoon, K. H. et al. Selective β-cell loss and α-cell expansion in patients with type 2 diabetes mellitus in Korea. J. Clin. Endocrinol. Metab. 88, 2300-2308 (2003).
31. Suraamornkul, S., Kwancharoen, R., Ovartlarnporn, M., Rawdaree, P. & Bajaj, M. Insulin clamp-derived measurements of insulin sensitivity and insulin secretion in lean and obese Asian type 2 diabetic patients. Metab. Syndr. Relat. Disord. 8, 113-118 (2010).
32. Liguori, A. et al. Effect of glycaemic control and age on low-density lipoprotein susceptibility to oxidation in diabetes mellitus type 1. Eur. Heart J. 22, 2075-2084 (2001).
33. Chen, J. & Mehta, J. L. Interaction of oxidized low-density lipoprotein and the renin-angiotensin system in coronary artery disease. Curr. Hypertens. Rep. 8, 139-143 (2006).
34. Singh, B. M. & Mehta, J. L. Interactions between the renin-angiotensin system and dyslipidemia: relevance in the therapy of hypertension and coronary heart disease. Arch. Intern. Med. 163, 1296-1304 (2003).
35. Yang, X. et al. Additive interaction between the renin-angiotensin system and lipid metabolism for cancer in type 2 diabetes. Diabetes 58, 1518-1525 (2009).
36. Silvente-Poirot, S. & Poirot, M. Cancer. Cholesterol and cancer, in the balance. Science 343, 1445-1446 (2014).
37. Yang, X. L. & Chan, J. C. Metformin and the risk of cancer in type 2 diabetes: methodological challenges and perspectives. Ann. Transl Med. 2, 52 (2014).
38. Yang, X. et al. Renin-angiotensin system inhibitors may attenuate low LDL cholesterol-related cancer risk in type 2 diabetes. Diabetes Metab. Res. Rev. 30, 415-423 (2014).
39. Towler, M. C. & Hardie, D. G. AMP-activated protein kinase in metabolic control and insulin signaling. Circ. Res. 100, 328-341 (2007).
40. Kim, I. & He, Y. Y. Targeting the AMP-activated protein kinase for cancer prevention and therapy. Front. Oncol. 3, 175 (2013).
41. Hardie, D. G. AMPK: a target for drugs and natural products with effects on both diabetes and cancer. Diabetes 62, 2164-2172 (2013).
42. Stephenne, X. et al. Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status. Diabetologia 54, 3101-3110 (2011).
43. Dowling, R. J., Zakikhani, M., Fantus, I. G., Pollak, M. & Sonenberg, N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 67, 10804-10812 (2007).
44. Alimova, I. N. et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 8, 909-915 (2009).
45. Hofmann, J. Protein kinase C isozymes as potential targets for anticancer therapy. Curr. Cancer Drug Targets 4, 125-146 (2004).
46. Buzzai, M. et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 67, 6745-6752 (2007).
47. Murao, K. et al. Effects of glucose and insulin on rat apolipoprotein A-I gene expression. J. Biol. Chem. 273, 18959-18965 (1998).
48. Han, R. et al. Apolipoprotein A-I stimulates AMP-activated protein kinase and improves glucose metabolism. Diabetologia 50, 1960-1968 (2007).
49. Kimura, T. et al. Mechanism and role of high density lipoprotein-induced activation of AMP-activated protein kinase in endothelial cells. J. Biol. Chem. 285, 4387-4397 (2010).
50. Cazzaniga, M., Bonanni, B., Guerrieri-Gonzaga, A. & Decensi, A. Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiol. Biomarkers Prev. 18, 701-705 (2009).
51. Samani, A. A., Yakar, S., LeRoith, D. & Brodt, P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr. Rev. 28, 20-47 (2007).
52. Moschos, S. J. & Mantzoros, C. S. The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology 63, 317-332 (2002).
53. Godsland, I. F. Insulin resistance and hyperinsulinaemia in the development and progression of cancer. Clin. Sci. (Lond.) 118, 315-332 (2010).
54. LeRoith, D. et al. Obesity and type 2 diabetes are associated with an increased risk of developing cancer and a worse prognosis; epidemiological and mechanistic evidence. Exp. Clin. Endocrinol. Diabetes 116 (Suppl. 1), S4-S6 (2008).
55. Hemkens, L. G. et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52, 1732-1744 (2009).
56. Andersen, A. S. et al. Identification of determinants that confer ligand specificity on the insulin receptor. J. Biol. Chem. 267, 13681-13686 (1992).
57. Slaaby, R. et al. Hybrid receptors formed by insulin receptor (IR) and insulin-like growth factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity irrespective of the IR splice variant. J. Biol. Chem. 281, 25869-25874 (2006).
58. Felig, P. in Metabolic Control and Disease (eds Bondy, P. K. & Rosenberg, L. E.) 277-301 (Saunders, 1980).
59. Carlberg, M. et al. Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme A reductase and cell growth. J. Biol. Chem. 271, 17453-17462 (1996).
60. Brown, M. S. & Goldstein, J. L. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89, 331-340 (1997).
61. Eberle, D., Hegarty, B., Bossard, P., Ferre, P. & Foufelle, F. SREBP transcription factors: master regulators of lipid homeostasis. Biochimie 86, 839-848 (2004).
62. Shimomura, I. et al. Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc. Natl Acad. Sci. USA 96, 13656-13661 (1999).
63. Bhasker, C. R. & Friedmann, T. Insulin-like growth factor-1 coordinately induces the expression of fatty acid and cholesterol biosynthetic genes in murine C2C12 myoblasts. BMC Genomics 9, 535 (2008).
64. Du, X., Kristiana, I., Wong, J. & Brown, A. J. Involvement of Akt in ER-to-Golgi transport of SCAP/SREBP: a link between a key cell proliferative pathway and membrane synthesis. Mol. Biol. Cell 17, 2735-2745 (2006).
65. Luu, W., Sharpe, L. J., Stevenson, J. & Brown, A. J. Akt acutely activates the cholesterogenic transcription factor SREBP-2. Biochim. Biophys. Acta 1823, 458-464 (2012).
66. Krycer, J. R., Sharpe, L. J., Luu, W. & Brown, A. J. The Akt-SREBP nexus: cell signaling meets lipid metabolism. Trends Endocrinol. Metab. 21, 268-276 (2010).
67. Eggert, M. L. et al. Cross-sectional and longitudinal relation of IGF1 and IGF-binding protein 3 with lipid metabolism. Eur. J. Endocrinol. 171, 9-19 (2014).
68. Paolisso, G. et al. Serum levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 in healthy centenarians: relationship with plasma leptin and lipid concentrations, insulin action, and cognitive function. J. Clin. Endocrinol. Metab. 82, 2204-2209 (1997).
69. Vigil, D., Cherfils, J., Rossman, K. L. & Der, C. J. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat. Rev. Cancer 10, 842-857 (2010).
70. Shimizu, M. et al. Pitavastatin suppresses diethylnitrosamine-induced liver preneoplasms in male C57BL/KsJ-db/db obese mice. BMC Cancer 11, 281 (2011).
71. Yasuda, Y. et al. Pitavastatin inhibits azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice. Cancer Sci. 101, 1701-1707 (2010).
72. Ko, G. T. et al. Effect of interactions between C peptide levels and insulin treatment on clinical outcomes among patients with type 2 diabetes mellitus. CMAJ 180, 919-926 (2009).
73. Schrijvers, B. F., De Vriese, A. S. & Flyvbjerg, A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr. Rev. 25, 971-1010 (2004).
74. Sugimoto, M. et al. Influences of chymase and angiotensin I-converting enzyme gene polymorphisms on gastric cancer risks in Japan. Cancer Epidemiol. Biomarkers Prev. 15, 1929-1934 (2006).
75. George, A. J., Thomas, W. G. & Hannan, R. D. The renin-angiotensin system and cancer: old dog, new tricks. Nat. Rev. Cancer 10, 745-759 (2010).
76. Jia, G., Aggarwal, A., Yohannes, A., Gangahar, D. M. & Agrawal, D. K. Cross-talk between angiotensin II and IGF-1-induced connexin 43 expression in human saphenous vein smooth muscle cells. J. Cell. Mol. Med. 15, 1695-1702 (2011).
77. Yasumaru, M. et al. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway. Cancer Res. 63, 6726-6734 (2003).
78. Yang, X. et al. Low LDL cholesterol, albuminuria, and statins for the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes Care 32, 1826-1832 (2009).
79. Sui, Y. et al. Pancreatic islet β-cell deficit and glucose intolerance in rats with uninephrectomy. Cell. Mol. Life Sci. 64, 3119-3128 (2007).
80. Zhao, H. L. et al. Fat redistribution and adipocyte transformation in uninephrectomized rats. Kidney Int. 74, 467-477 (2008).
81. De Mitri, M. S., Cassini, R. & Bernardi, M. Hepatitis B virus-related hepatocarcinogenesis: molecular oncogenic potential of clear or occult infections. Eur. J. Cancer 46, 2178-2186 (2010).
82. Yamasaki, K., Hayashi, Y., Okamoto, S., Osanai, M. & Lee, G. H. Insulin-independent promotion of chemically induced hepatocellular tumor development in genetically diabetic mice. Cancer Sci. 101, 65-72 (2010).
83. Tsan, Y. T., Lee, C. H., Wang, J. D. & Chen, P. C. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J. Clin. Oncol. 30, 623-630 (2012).
84. Yang, X. et al. Enhancers and attenuators of risk associations of chronic hepatitis B virus infection with hepatocellular carcinoma in type 2 diabetes. Endocr. Relat. Cancer 20, 161-171 (2013).
85. Melvin, J. C., Holmberg, L., Rohrmann, S., Loda, M. & Van Hemelrijck, M. Serum lipid profiles and cancer risk in the context of obesity: four meta-analyses. J. Cancer Epidemiol. 2013, 823849 (2013).
86. Dombrowski, F., Bannasch, P. & Pfeifer, U. Hepatocellular neoplasms induced by low-number pancreatic islet transplants in streptozotocin diabetic rats. Am. J. Pathol. 150, 1071-1087 (1997).
87. Shafie, S. M. & Grantham, F. H. Role of hormones in the growth and regression of human breast cancer cells (MCF-7) transplanted into athymic nude mice. J. Natl Cancer Inst. 67, 51-56 (1981).
88. Goodwin, P. J. et al. Insulin-and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations. J. Clin. Oncol. 30, 164-171 (2012).
89. Onitilo, A. A. et al. Type 2 diabetes mellitus, glycemic control, and cancer risk. Eur. J. Cancer Prev. 23, 134-140 (2014).
90. Calle, E. E. & Kaaks, R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer 4, 579-591 (2004).
91. Chan, J. C., Zhang, Y. & Ning, G. Diabetes in China: a societal solution for a personal challenge. Lancet Diabetes Endocrinol. 2, 969-979 (2014).
92. Weinstein, I., Patel, T. B. & Heimberg, M. Secretion of triglyceride and ketogenesis by livers from spontaneous diabetic BB Wistar rats. Biochem. Biophys. Res. Commun. 176, 1157-1162 (1991).
93. Yoshino, G. et al. Effect of long-term insulin deficiency and insulin treatment on the composition of triglyceride-rich lipoproteins and triglyceride turnover in rats. Atherosclerosis 92, 243-250 (1992).
94. Kraemer, F. B. Insulin deficiency alters cellular cholesterol metabolism in murine macrophages. Diabetes 35, 764-770 (1986).
95. Pischon, T. et al. General and abdominal adiposity and risk of death in Europe. N. Engl. J. Med. 359, 2105-2120 (2008).
96. Davis-Yadley, A. H. et al. Ethnic disparities in the risk of colorectal adenomas associated with lipid levels: a retrospective multiethnic study. J. Gastrointest. Cancer 46, 29-35 (2015).
97. Yang, X. et al. White blood cell count and renin-angiotensin system inhibitors for the risk of cancer in type 2 diabetes. Diabetes Res. Clin. Pract. 87, 117-125 (2010).
98. Ma, R. C. & Chan, J. C. Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States. Ann. NY Acad. Sci. 1281, 64-91 (2013).
99. Whiting, D. R., Guariguata, L., Weil, C. & Shaw, J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res. Clin. Pract. 94, 311-321 (2011).
100. Ranc, K., Jorgensen, M. E., Friis, S. & Carstensen, B. Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment. Diabetologia 57, 927-934 (2014).